Want to see RXRX full AI Analyst Report?
RXRX Stock Chart & Stats
$3.56
-$0.05(-1.66%)
At close: 4:00 PM EDT
$3.56
-$0.05(-1.66%)
Day’s Range― - ―
52-Week Range$2.77 - $7.18
Previous CloseN/A
Volume16.53M
Average Volume (3M)14.22M
Market Cap
$1.90B
Enterprise Value$1.47K
Total Cash (Recent Filing)$545.68M
Total Debt (Recent Filing)$61.88M
Price to Earnings (P/E)―
Beta3.13
Next Earnings
Nov 11, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding535,342,160
10 Day Avg. Volume13,430,410
30 Day Avg. Volume14,220,236
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.62
Price to Sales (P/S)24.50
P/FCF Ratio-4.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.43Price Target Upside80.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$50.47M
Bulls Say, Bears Say
Bulls Say
Proprietary Data And AI PlatformThe company’s large proprietary datasets and integrated AI workflows can create a durable discovery advantage by improving model quality and biological insight over time. This data factory is difficult to reproduce quickly and supports both internal programs and partner-sponsored research.
Partnership Validation And FundingSubstantial realized partnership payments provide external validation of Recursion’s platform and help finance continued development without relying solely on equity markets. Additional milestone opportunities and potential royalties could expand the economic value of these strategic relationships.
Pipeline Productivity And Clinical ProgressA growing clinical pipeline and encouraging early efficacy indicate that Recursion is converting its computational platform into drug candidates with measurable clinical signals. Faster candidate design may improve capital efficiency and broaden the company’s ability to advance multiple programs.
Bears Say
Persistent Losses And Cash BurnHeavy recurring cash consumption shows that the business is not yet self-funding and remains dependent on cash reserves, partnerships, or future financing. Continued burn can reduce financial flexibility and increase the risk of equity dilution before product revenue becomes meaningful.
Weak Current Revenue EconomicsDeclining revenue and negative gross profit indicate that current collaboration economics do not yet cover the cost of the operating platform and development portfolio. Limited operating leverage makes durable profitability dependent on stronger partnerships, milestones, or successful product approvals.
Clinical And Regulatory Execution RiskKey value drivers remain exposed to uncertain clinical outcomes, regulatory requirements, and lengthy development timelines. Delayed or unfavorable data could weaken partnership and financing support, while the timing of milestones may extend beyond the company’s stated early-2028 cash runway.
Recursion Pharmaceuticals News
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $2.77 and its highest was $7.18 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Recursion Pharmaceuticals’s market cap is $1.90B.
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 53 days.
How were Recursion Pharmaceuticals’s earnings last quarter?
Recursion Pharmaceuticals released its earnings results on Aug 05, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.24 by -$0.01.
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -0.22.
How many shares outstanding does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 535,342,160 shares outstanding.
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Recursion Pharmaceuticals reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.24. Following the earnings report the stock price went down -4.23%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Currently, no hedge funds are holding shares in RXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recursion Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.43 (80.71% Upside)
$6.43 (80.71% Upside)
Blogger Sentiment
Neutral
RXRX Sentiment 50%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Company Deck
RXRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strong set of operational and technical highlights: multiple advancing clinical programs with compelling early efficacy (REC-4881), a cleared IND for a precision-selective oncology candidate (REC-7735), large proprietary data assets (>50 PB, massive cellular atlases), meaningful partnership cash inflows (> $500M realized, > $260M from Roche-Genentech) and demonstrated efficiency gains in design speed and operating costs (guidance lowered to $375M, ~40% reduction vs 2024 pro forma). Key risks and lowlights are typical for a clinical-stage biotech: regulatory and clinical uncertainty in rare disease and CNS programs, timing of pivotal data (some milestones extend beyond the current cash runway), competitive pressure as AI tools proliferate, and the early-stage nature of some proofs. Overall, positive operational momentum and external validation from partners outweigh the remaining clinical and market risks, but the company still faces execution and timing risks as programs advance.View all RXRX earnings summariesRXRX Stock 12 Month Forecast
Average Price Target
$6.43
▲(80.71% Upside)
Technical Analysis
Ownership Overview
2.88% Insiders
12.72% Mutual Funds
22.98% Other Institutional Investors
33.31% Public Companies and Individual Investors